Prospective, multi-center, randomized, open label, active control, phase 2 clinical study to evaluate immunogenicity, safety and tolerability of single heterologous booster dose of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences against SARS-CoV-2 Virus) with Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus) - NA

开始日期2023-11-01

申办/合作机构

Reliance Life Sciences Pvt Ltd.

PACTR202307772264605 / Suspended临床2期

Prospective, multi-center, randomized, open label, active controlled, seamless phase 2/phase3 clinical study to evaluate immunogenicity, safety and tolerability of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences Pvt Ltd. against SARS-CoV-2 Virus) and Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus) administered as primary vaccination.

开始日期2023-08-01

申办/合作机构

Reliance Life Sciences Pvt Ltd.

100 项与 RelCoVax 相关的临床结果

登录后查看更多信息

100 项与 RelCoVax 相关的转化医学

登录后查看更多信息

100 项与 RelCoVax 相关的专利（医药）

登录后查看更多信息

项与 RelCoVax 相关的文献（医药）

2024-02-01·Vaccine

Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus

Article

作者: Nalband, Hassan ; Vidyadhar Reddy, G E C ; Gokhale, Abhiram ; Bhavsar, Mahesh ; Shaikh, Sameer ; Pusalkar, Rakhi ; Gadiparthi, Anjaneyulu ; Parte, Leena ; Phatarphekar, Abhishek ; Karanam, Gopala ; Sensarma, Sayandev ; Harinarayana Rao, S ; Sivashanmuganathan, S ; Ramnath, R L ; Anandan, Sathyavathy ; Pratapreddy, K ; Masand, Girish ; Kad, Satish ; Sathe, Nikhil ; Ramana, Venkata ; Sangapillai, R ; Rao, Praveen

SARS-CoV-2, severe acute respiratory syndrome coronavirus-2, causes coronavirus disease- 2019 (COVID-19). Mostly, COVID-19 causes respiratory symptoms that can resemble those of a cold, the flu, or pneumonia. COVID-19 may harm more than just lungs and respiratory systems. It may also have an impact on other parts of the body and debilitating effects on humans, necessitating the development of vaccines at an unprecedented rate in order to protect humans from infections. In response to SARS-CoV-2 infection, mRNA, viral vector-based carrier and inactivated virus-based vaccines, as well as subunit vaccines, have recently been developed. We developed Relcovax®, a dual antigen (Receptor binding domain (RBD) and Nucleocapsid (N) proteins) subunit protein vaccine candidate. Preliminary mouse preclinical studies revealed that Relcovax® stimulates cell-mediated immunity and provides broader protection against two SARS-CoV-2 variants, including the delta strain. Before conducting human studies, detailed preclinical safety assessments are required, so Relcovax® was tested for safety, and immunogenicity in 28-day repeated dose toxicity studies in rats and rabbits. In the toxicity studies, there were no mortality or morbidity, abnormal clinical signs, abnormalities in a battery of neurobehavioral observations, abnormalities in detailed clinical and ophthalmological examinations, or changes in body weights or feed consumption. In any of the studies, no abnormal changes in organ weights, haematology, clinical chemistry, urinalysis parameters, or pathological findings were observed. Immunogenicity tests on rats and rabbits revealed 100 % seroconversion. Relcovax® was therefore found to be safe in animals, with a No Observed Adverse Effect Level (NOAEL) of 20 µg/protein in rats and rabbits. In efficacy studies, Relcovax® immunised hamsters demonstrated dose-dependent protection against SARS-CoV-2 infection, with a high dose (20 µg/protein) being the most protective, while in cynomolgus macaque monkey study, lowest dose 5 µg/protein had the highest efficacy. In conclusion, Relcovax® was found to be safe, immunogenic, and efficacious in in vivo studies.

2022-07-01·Vaccine

RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice

Article

作者: Gokhale, Abhiram ; Pratap Reddy, K ; Vijayan, Vijita ; Pagare, Shyam ; Khadpe, Nilesh ; Vidyadhar Reddy, G E C ; Ramana, Venkata ; Ramnath, R L ; Shinde, Ketaki ; Pai, Sangita S ; Rao, Praveen ; Harinarayana Rao, S ; Karanam, Gopala ; Phatarphekar, Abhishek ; Kuchroo, Pushpa ; Masand, Girish

The COVID-19 pandemic has spurred an unprecedented movement to develop safe and effective vaccines against the SARS-CoV-2 virus to immunize the global population. The first set of vaccine candidates that received emergency use authorization targeted the spike (S) glycoprotein of the SARS-CoV-2 virus that enables virus entry into cells via the receptor binding domain (RBD). Recently, multiple variants of SARS-CoV-2 have emerged with mutations in S protein and the ability to evade neutralizing antibodies in vaccinated individuals. We have developed a dual RBD and nucleocapsid (N) subunit protein vaccine candidate named RelCoVax® through heterologous expression in mammalian cells (RBD) and E. coli (N). The RelCoVax® formulation containing a combination of aluminum hydroxide (alum) and a synthetic CpG oligonucleotide as adjuvants elicited high antibody titers against RBD and N proteins in mice after a prime and boost dose regimen administered 2 weeks apart. The vaccine also stimulated cellular immune responses with a potential Th1 bias as evidenced by increased IFN-γ release by splenocytes from immunized mice upon antigen exposure particularly N protein. Finally, the serum of mice immunized with RelCoVax® demonstrated the ability to neutralize two different SARS-CoV-2 viral strains in vitro including the Delta strain that has become dominant in many regions of the world and can evade vaccine induced neutralizing antibodies. These results warrant further evaluation of RelCoVax® through advanced studies and contribute towards enhancing our understanding of multicomponent subunit vaccine candidates against SARS-CoV-2.

100 项与 RelCoVax 相关的药物交易

登录后查看更多信息